Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes

被引：0
|
作者：
Nowell, E. [1 ]
Laird, S. [1 ]
Bailey, E. [1 ]
Brownson, E. [1 ]
Saunders, J. [1 ]
Seenan, J. P. [1 ]
Smith, G. [1 ]
Macdonald, J. [1 ]
机构：
[1] NHS Greater Glasgow & Clyde, Gastroenterol, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P705
引用
收藏
页码：837 / 837
页数：1
相关论文
共 50 条
  • [1] Patient benefits of switching from intravenous to subcutaneous infliximab
    Rahmany, Sohail
    Young, David
    Latter, Sue
    Cummings, Fraser
    GUT, 2023, 72 (SUPPL_2) : A105 - A105
  • [2] Switching from intravenous to subcutaneous Infliximab in patients with immune mediated diseases in clinical remission
    Viazis, N.
    Karamanakos, A.
    Mousourakis, K.
    Christidou, A.
    Fousekis, F.
    Mpakogiannis, K.
    Koukoudis, A.
    Katsanos, K.
    Christodoulou, D.
    Cheila, M.
    Tzouvala, M.
    Zacharopoulou, E.
    Palatianou, M.
    Giouleme, O.
    Katsoula, A.
    Liatsos, C.
    Kyriakos, N.
    Zampeli, E.
    Papathanasiou, E.
    Theodoropoulou, A.
    Karmiris, K.
    Psaroudakis, I
    Tribonias, G.
    Gazi, S.
    Mole, E.
    Dimitroulas, T.
    Koutsianas, C.
    Vasilopoulos, D.
    Fragoulis, G.
    Michalakeas, N.
    Papagoras, C.
    Panagakis, P.
    Papoutsaki, M.
    Chasapi, V
    Stratigos, A.
    Katsikas, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1773 - i1773
  • [3] Switching from intravenous to subcutaneous infliximab in patients with hidradenitis suppurativa
    Luque, Mar
    Barboza, Lorenza
    Sandoval, Alejandra
    Fuertes, Irene
    EXPERIMENTAL DERMATOLOGY, 2023, 32 : 145 - 145
  • [4] The East Kent experience of switching from intravenous infliximab to subcutaneous, benefits to the patients, the service and financial implications
    Abreu, B.
    Scott, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I2239 - I2239
  • [5] Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
    Remy, Clotilde
    Caron, Benedicte
    Gouynou, Celia
    Haghnejad, Vincent
    Jeanbert, Elodie
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (24)
  • [6] Efficacy and Safety of Switching From Intravenous to Subcutaneous Infliximab for Psoriasis: A Case Series
    Larney, Conor
    Foley, Peter
    Gebauer, Kurt
    Daniel, Benjamin S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024,
  • [7] Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab
    Sed, N. Piazza O.
    Maregatti, M. C.
    Pessarelli, T.
    Vigano, C.
    Conforti, F.
    Noviello, D.
    Bezzio, C.
    Amoroso, C.
    Molteni, C.
    Anolli, M. P.
    Pirola, L.
    Saibeni, S.
    Fraquelli, M.
    Vecchi, M.
    Caprioli, F.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1669 - I1669
  • [8] Treatment persistence, clinical, and biological outcomes following an elective switch from intravenous to subcutaneous infliximab and vedolizumab
    Outtier, A.
    Hoffert, Y.
    De Dycker, E.
    Geens, P.
    Lambrechts, T.
    Loddewijkx, E.
    Paps, A.
    Verstockt, B.
    Sabino, J.
    Vermeire, S.
    Ferrante, M.
    TARGID
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1434 - i1435
  • [9] Is Also the Patient Ready for Switching from Intravenous to Subcutaneous Biologics?
    Asnong, Katrien
    Pouillon, Lieven
    Bossuyt, Peter
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (03): : 515 - 516
  • [10] Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure
    Bae, J. H.
    Park, J. B.
    Baek, J. E.
    Hong, S. W.
    Park, S. H.
    Yang, D. H.
    Ye, B. D.
    Byeon, J. S.
    Myung, S. J.
    Yang, S. K.
    Hwang, S. W.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1131 - I1133
12345